Upregulation of biomarkers, including PSA, prostatic acid phosphatase, and prostein, in prostate cancer may involve altered endosome trafficking kinetics that regulate protein localisation, degradation, and secretion, and is likely controlled by changes in vesicular trafficking machinery (Figure 7A) [34,35,197]. This evidence concerns the gene SLC45A3 and prostate carcinoma.